79822-14-3

Upstream product

• 4619-20-9 3-(4-methylbenzoyl)propionic acid 
• 108-88-3 toluene 

Downstream Products

• 52240-22-9 4-(3-amino-4-methyl-phenyl)-4-oxo-butyric acid 
• 141-82-2 malonic acid 
• 96-98-0 4-methyl-3-nitrobenzoic acid 
• 61495-09-8 4-(3-methoxy-4-methyl-phenyl)-4-oxo-butyric acid 
• 122334-02-5 4-(3-methoxy-4-methylphenyl)butanoic acid 
• 56872-34-5 3-(3-hydroxy-4-methylbenzoyl)-propionic acid 

Relevant academic research and scientific papers

Synthesis, Molecular Docking and Potential Antioxidant Activity of Di/Trisubstituted Pyridazinone Derivatives

A number of pyridazinone derivatives bearing substituted benzylidene and heterocyclic/aromatic rings at 4th and 6th positions, respectively were synthesized in good to moderate yields and screened for antioxidant activity. Antioxidant activity of pyridazinone derivatives was evaluated by using several in vitro radical scavenging methods such as 1,1-diphenylpicrylhydrazyl (DPPH), hydrogen peroxide (H2O2), nitric oxide (NO), reducing power, and metal chelating assay etc. Molegro virtual docker software was used to study the binding affinity of the title compounds with the xanthine oxidoreductase enzyme. Amongst the tested compounds, 5a, 5d, 5g & 5j were found to exhibit excellent antioxidant activity at par with the positive control, ascorbic acid. The molecular docking studies of these compounds demonstrated a good selectivity profile with xanthine oxidoreductase receptors. A preliminary study of the structural-activity relationship showed that the presence of electron withdrawing group and heterocyclic ring on pyridazinone nucleus are associated with the best potency and selectivity profile. It could be proposed that xanthine oxidoreductase receptor may be involved in observed antioxidant activity of pyridazinone derivatives bearing aromatic ring and benzylidene substituents and thus the synthesized compounds are worthy of further exploration.

HYBRID NECROPTOSIS INHIBITORS

The present invention relates to heterocyclic compounds (e.g., compounds described by Formula (I)) and pharmaceutically acceptable salts thereof. The invention also features pharmaceutical compositions that include these compounds and their use in therapy for treating conditions in which necroptosis is likely to play a substantial role. The heterocyclic compounds described herein can also achieve improved activity and selectivity towards RIP1 and/or RIP3.